January 8, 2026- Thermo Fisher Scientific Inc. announced the enrollment of the first patient in the new PPD™ CorEvitas™ Obesity Registry. This prospective, observational registry will generate real-world evidence on the long-term effectiveness, safety and patient experience associated with obesity management therapies, including anti-obesity medications. By collecting insights directly from both clinicians and patients, the registry will provide critical insights into treatment patterns, adherence, satisfaction and clinical outcomes, including anthropomorphic measures, across diverse care settings.